English
Regional settings| Spread | 0.021 | ||||
 Long position overnight feeLong position overnight fee
Trade size with leverage ~ SGD 5,000.00 Short position overnight fee ~ SGD 4,000.00 | -0.020845% | ||||
| Short position overnight fee Short position overnight fee
Trade size with leverage ~ SGD 5,000.00 Short position overnight fee ~ SGD 4,000.00 | -0.001073% | ||||
| Overnight fee time | 21:00 (UTC) | ||||
| Currency | SGD | ||||
| Min traded quantity | 1 | ||||
| Margin | 20 | ||||
| Stock exchange | Singapore | ||||
| Commission on trade1 | 0% |
Information_provided_by_capital
1Our charge for executing your trade is the spread, the difference between the buy and sell price. Please consult the Charges and Fees section of our website for further information
| Prev. Close | 0.397 |
| Open | 0.402 |
| 1-Year Change | -1.23% |
| Day's Range | 0.402 - 0.402 |
TalkMed Group Limited is a Singapore-based investment holding company. The Company’s Oncology services segment is engaged in the provision of oncology services to Parkway Cancer Centre, a division of Parkway Hospitals Singapore Pte. Ltd., Thu Cuc International General Hospital in Hanoi, Vietnam and Hong Kong Integrated Oncology Centre Holdings Limited. The Company has expanded its oncology services to China. Its Stem cell related products and services segment is engaged in the provision of services related to processing, culturing and storage of stem cells through its subsidiary, Stem Med Pte. Ltd. (Stem Med) to Parkway Cancer Centre, a division of Parkway Hospitals Singapore Pte. Ltd., StemCord Pte Ltd, the non-controlling shareholder of Stem Med and other individual customers. The Cellular and gene therapy related products and services segment is engaged in the provision of goods and services related to cellular and gene therapy through its subsidiary, CellVec Pte. Ltd.
BRIEF: For the fiscal year ended 31 December 2021, TalkMed Group Ltd revenues decreased 2% to SP$60.7M. Net income increased 10% to SP$25.1M. Revenues reflect a decrease in demand for the Company's products and services due to unfavorable market conditions. Net income reflects Impairment loss decrease from SP$3.4M (expense) to SP$0K, Cost of share-based payments to employee decrease of 76% to SP$512K (expense).
